Pfizer May Expand Generic Presence, Building On Greenstone
This article was originally published in The Pink Sheet Daily
Pfizer is assessing "opportunities in the area of generic markets," Global Pharmaceuticals President Karen Katen says. The company's recent launch of an "authorized" generic gabapentin is a "watershed moment."
You may also be interested in...
"At risk" launches of the first AB-rated Neurontin generics by Purepac and Teva are followed by Pfizer's own generic launch through Greenstone.
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.